Home » Headlines » Currently Reading:

Morning Headlines 2/19/21

February 18, 2021 Headlines No Comments

Leading Imaging Software Company Intelerad Medical Systems Announces Acquisition of LUMEDX

Imaging vendor Intelerad acquires Lumedx, which offers cardiovascular information systems and analytics.

Carevive Closes Oversubscribed $18M Series C Equity Raise

Cancer care management software vendor Carevive raises $18 million in a Series C funding round.

IBM Explores Sale of IBM Watson Health

Sources say IBM is considering selling its IBM Watson Health business, which includes Merge Healthcare, Phytel, and Truven Health Analytics.

Olive founder Sean Lane raises $50M to start Medicaid managed care company

Olive CEO Sean Lane will soon launch Circulo, a managed care company that will leverage Olive’s AI, automation, and data analytics.

Google to open first Minnesota office to advance Mayo Clinic cloud partnership

Google will open an office in Rochester, MN to better facilitate its work with Mayo Clinic, which includes projects related to engineering, AI, and machine learning.



HIStalk Featured Sponsors

     

Text Ads


RECENT COMMENTS

  1. Ageed Mike, "patients are the widgets that must be processed" additionally when it costs close to $3,700 a month for…

  2. The TSA-ification of every aspect of American society continues at pace. Race to the bottom, and technology amplifies the obvious…

  3. I dont think anything will change until Dr Jayne and others take my approach of naming names, including how much…

  4. My husband was in the ER, upon discharge we were handed discharge papers, after getting home we realized they were…

  5. I love the community health center that serves as my medical home, but they regularly ask me to sign forms…

Founding Sponsors


 

Platinum Sponsors


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gold Sponsors


 

 

 

 

 

 

 

 

RSS Webinars

  • An error has occurred, which probably means the feed is down. Try again later.